Anti-Microbial Savior BioteQ Co., Ltd. (TPEX:6864)
Taiwan · Delayed Price · Currency is TWD 41.30
+0.10 (0.24%)
Aug 4, 2026, 12:54 PM CST
TPEX:6864 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 466.22 | 194.13 | 78.43 | 131.11 | 166.58 |
Cash & Short-Term Investments | 466.22 | 194.13 | 78.43 | 131.11 | 166.58 |
Cash Growth | 140.16% | 147.53% | -40.18% | -21.29% | 80.36% |
Accounts Receivable | - | - | - | - | 0.07 |
Other Receivables | 0.08 | 0.54 | 0.43 | 0.1 | - |
Receivables | 0.08 | 0.54 | 0.43 | 0.1 | 0.07 |
Inventory | 1.65 | 2.18 | 0.51 | 0.33 | 0.84 |
Prepaid Expenses | 6.46 | 6.02 | 4.13 | 2.15 | 1.51 |
Total Current Assets | 474.41 | 202.86 | 83.49 | 133.69 | 169 |
Property, Plant & Equipment | 18.55 | 21.41 | 20.34 | 28.83 | 41.91 |
Long-Term Investments | - | - | 0.01 | 0.01 | 0.01 |
Long-Term Deferred Tax Assets | 22.22 | 22.22 | 22.22 | 17.21 | 8.44 |
Other Long-Term Assets | 5.24 | 1.69 | 1.99 | 2.23 | 1.81 |
Total Assets | 520.41 | 248.18 | 128.05 | 181.96 | 221.16 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | - | 0.27 | 0.27 | 0.93 |
Current Portion of Leases | 1.23 | 2.19 | 1.38 | 2.6 | 1.46 |
Current Income Taxes Payable | - | - | - | 0.7 | - |
Current Unearned Revenue | 0.13 | 0.19 | 0.13 | - | - |
Other Current Liabilities | 8.55 | 8.29 | 5.21 | 4.81 | 2.99 |
Total Current Liabilities | 9.92 | 10.67 | 6.99 | 8.39 | 5.38 |
Long-Term Debt | - | - | - | - | 9.17 |
Long-Term Leases | - | 0.19 | - | 1.38 | 2.68 |
Total Liabilities | 9.92 | 10.87 | 6.99 | 9.77 | 17.23 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 377.29 | 323.45 | 250 | 250 | 250 |
Additional Paid-In Capital | 313.91 | 117.97 | 0.64 | - | - |
Retained Earnings | -180.7 | -204.1 | -129.59 | -77.81 | -46.07 |
Shareholders' Equity | 510.49 | 237.31 | 121.05 | 172.2 | 203.93 |
Total Liabilities & Equity | 520.41 | 248.18 | 128.05 | 181.96 | 221.16 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.23 | 2.39 | 1.38 | 3.99 | 13.31 |
Net Cash (Debt) | 464.99 | 191.74 | 77.04 | 127.13 | 153.27 |
Net Cash Growth | 142.51% | 148.87% | -39.40% | -17.06% | 73.60% |
Net Cash Per Share | 14.31 | 6.33 | 3.08 | 5.09 | 8.16 |
Filing Date Shares Outstanding | 37.82 | 30.29 | 24.99 | 24.99 | 21.61 |
Total Common Shares Outstanding | 37.73 | 30.29 | 24.99 | 24.99 | 21.61 |
Working Capital | 464.49 | 192.19 | 76.5 | 125.31 | 163.62 |
Book Value Per Share | 13.53 | 7.83 | 4.84 | 6.89 | 9.44 |
Tangible Book Value | 510.49 | 237.31 | 121.05 | 172.2 | 203.93 |
Tangible Book Value Per Share | 13.53 | 7.83 | 4.84 | 6.89 | 9.44 |